news release 12th November 2021

Birkenhead, Friday, November 12, 2021

Birkenhead UK November 12, 2021/PRNewswire/ — Alterola Biotech Inc. (OTC: ABTI)

Alterola Biotech Inc. Registration Statement Declared Effective

(“Alterola” or the “Company”), a preclinical-stage biotechnology company focused on developing cannabinoid therapies for the treatment of diseases, having filed its Registration Statement on Form S- 1 with the Securities and Exchange Commission on the 19th of October 2021, has been informed that the Registration Statement has been declared effective.

The Company intends to use the net proceeds from the Offering to advance the Company’s research and clinical development programs, additional product development, and for general corporate purposes.

Following its Common Stock Purchase Agreement with EMC2 on August 11 th , the Offering is expected to be priced in the context of the market, with the final terms of the Offering to be determined at the time of pricing. There can be no assurance as to whether or when the Offering may be completed, or as to the actual size or terms of the Offering.

The Prospectus contains important detailed information about the Offering and Is located on EDGAR at Prospective investors should read the Prospectus before making an investment decision.

This news release does not constitute an offer of any securities for sale.


If you would like more information about this topic, please call Investor Relations at +353 86 838 9812, or email

About Alterola Biotech Inc.
Alterola is a UK based pharmaceutical company developing cannabinoid, cannabinoid-like, and non- cannabinoid pharmaceutical active pharmaceutical ingredients (APIs). pharmaceutical medicines made from cannabinoid, cannabinoid-like, and non-cannabinoid APIs and targeting European novel food approval of cannabinoid-based, cannabinoid-like and non-cannabinoid ingredients and products.

Cautionary statement regarding forward-looking information:
This news release contains forward-looking statements that reflect Alterola’s current expectations regarding future events, including statements regarding financial performance, the timing of preclinical studies and clinical trials, the timing and outcomes of regulatory or intellectual property decisions, the relevance of Alterola product candidates currently in development. Forward-looking statements involve risks and uncertainties. Actual events could differ materially from those projected herein and depend on a number of factors, including (inter alia), the success of Alterola’s research and development strategies, the applicability of the discoveries made therein, the successful and timely completion and uncertainties related to the regulatory process, and the potential acceptance of any future product that may (if ever) be approved by the appropriate regulatory authorities by consumer and medical professionals. A further list and description of risks and uncertainties associated with an investment in Alterola can be found in Alterola’s filings with the U.S. Securities and Exchange Commission. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Alterola undertakes no obligation to update or revise the information contained in this press release, whether as a result of new information, future events or circumstances or otherwise.